Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Disease

HEIDELBERG, Germany--(BUSINESS WIRE)--#AFT--Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces it has raised USD 53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised USD 115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding